Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sanjeev Luther
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Beta
- 2.62
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -64.29
Financials
Revenue
$0.00-100.0%Net Income
$-4.01MEBITDA
$-4.01MFree Cash Flow
$-4.16MEPS (diluted)
$-3.40Shares Outstanding (diluted)
1.18M+1324.8%Operating Expenses
$4.10MCash & Debt
$5.03MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-14.08M | $-56.00 |
| 2024 | $582.0K | $-44.54M | $-39.25 |
| 2023 | $68.0K | $-21.67M | $-102.00 |
| 2022 | $0.00 | $-24.58M | $-201.50 |
| 2021 | $0.00 | $-122.55M | $-1415.25 |
| 2020 | $0.00 | $11.91M | $-87.75 |
| 2019 | $19.81M | $-2.05M | $-712.00 |
| 2018 | $23.34M | $-259.0K | $-96.25 |
| 2017 | $21.27M | $-1.08M | $-441.00 |
| 2016 | $22.31M | $-2.92M | $-1536.00 |
| 2015 | $24.52M | $-7.23M | $-3931.50 |
Valuation
ERNAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-40.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·5d ago·Negative
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1
View source ↗ - Newsglobenewswire.com·6d ago·Negative
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D. Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics
View source ↗ - Newsglobenewswire.com·21d ago·Negative
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC platform beyond oncology
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference Video webcast now available here
View source ↗ - Newsglobenewswire.com·57d ago·Neutral
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance
View source ↗
Earnings
Fri, Nov 6(in 4 weeks)
Consensus estimate $-3.84 per share
Typical surprise +46.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-3.40 vs $-3.30miss
- Mon, May 11$-6.95 vs $-1.95miss
- Fri, Nov 7$-0.15 vs $-33.00beat
- Wed, Aug 13$-0.61 vs $-39.00beat
- Wed, May 7$-2.25 vs $-48.00beat
- Thu, Mar 13$-48.00 vs $-37.50miss
Estimates and results for ERNA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ERNA officers and directors.
- Bought
- $44.8m
- Sold
- $4.5m
31 trades
1 trade
- Cherington Charlesbought
- Cherington Charlesbought
- Cherington Charlesbought
- Cherington Charlesbought
- Cherington Charlesbought
- Cherington Charlesbought
- Cherington Charlesbought
- Cherington Charlesbought
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ERNA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.